ArticleHealth science reports2026
Trimethoprim-Sulfamethoxazole in the Treatment of Idiopathic Granulomatous Mastitis: A Retrospective Cohort Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Idiopathic Granulomatous Mastitis (IGM) is a rare, chronic inflammatory breast condition with uncertain etiology and challenging management. Standard treatments often involve corticosteroids or surgery, both associated with significant relapse and adverse effects. Recent interest has emerged in using antibiotics such as Trimethoprim-Sulfamethoxazole (TMP-SMX) due to potential antimicrobial and anti-inflammatory benefits, though evidence remains limited. Methods: This retrospective cohort study evaluated the effectiveness and safety of TMP-SMX compared to conventional therapies in female patients diagnosed with histologically confirmed IGM. Patients were categorized into the TMP-SMX and control groups. Primary outcomes included treatment response and recurrence rates; secondary outcomes assessed changes in lesion size, clinical severity, and adverse events. Statistical analyzes included Chi-square, Fisher's exact test, and odds ratios (ORs) with 95% confidence intervals. Results: Complete clinical remission was achieved in 70.8% of TMP-SMX ( Conclusion: This study provides evidence that TMP-SMX is a safe and clinically effective alternative to corticosteroid-based regimens for managing idiopathic IGM. TMP-SMX demonstrated comparable efficacy, including favorable trends in lesion regression and disease severity improvement, with notably fewer systemic adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.